National Repository of Grey Literature 2 records found  Search took 0.01 seconds. 
Risk behaviour of people who inject drugs following treatment of hepatits C
Sedláková, Tereza ; Mravčík, Viktor (advisor) ; Janíková, Barbara (referee)
Background: In Czech Republic, 75-100 % of people newly diagnosed with hepatitis C type (VHC) are people who inject drugs (PWID). Currently, available treatment with direct-acting antiviral medicines without significant adverse side effects is fully covered by insurance. However, there is a risk of reinfection and insurance companies usually don't reimburse further treatment anymore. Aim: The aim of this study is to map and describe the development of risk behaviours in clients of low-threshold treatment programmes of the SEMIRAMIS and Laxus organisations (LSA partners) who have received treatment for hepatitis C. The research focuses on the circumstances of treatment, particularly barriers and supports to entry and the actual course of treatment. The sub-objectives are: to map the socio-economic situation of clients, to approximate patterns of use and to describe contacts with other services. In addition, to reveal the links between these factors and any changes in risk behaviour. Methods: Research was completed by metod of cross-sectional questionnaire surveys. The research sample consisted of 32 clients of LSA partners' low-threshold programs who had received at least one VHC treatment. The risk behaviours were monitored among following domains: a) injection use in general, b) unprotected...
Efficacy and treatment adherence to therapy of chronic HCV infection in people who inject drugs
Jandová, Zuzana ; Gabrhelík, Roman (advisor) ; Věchetová, Sonja (referee) ; Fraňková, Soňa (referee)
Backgrounds: Intravenous drug use represents the main route of transmission of hepatitis C virus infection (HCV). IVDU represent approximately 75-100% of newly diagnosed cases of HCV. IVDU have traditionally been considered as difficult-to-treat, owing to a low treatment adherence. The presumed low adherence to care in IVDU represent nowadays the barrier to therapy with direct-acting antivirals (DAA). Aims: The aim of the thesis was to assess efficacy of therapy of HCV with DAA and adherence to therapy in patients with history of IVDU. Comparing the results with the group of patients without IVDU, we would support the fact that the treatment efficacy in the IVDU group is high and that the utilisation of financial resources is effective. Methods: All consecutive patients who started DAA anti-HCV therapy at the Department of Hepatogastroenterology of Institute for Clinical and Experimental Medicine from 1st January 2017 to 6th August 2018 were included. The patients were divided into two groups: individuals with history of IVDU (IVDU, N = 101) and control group (Controls, N = 177), without IVDU in the past. The patients' data were obtained from patients medical charts during treatment and follow-up. Results: IVDU group achieved an SVR12 of 98% (vs. 98% in controls, N. S.). Two IVDU patients who were...

Interested in being notified about new results for this query?
Subscribe to the RSS feed.